- Home
- ICCM
ICCM
IceCure Medical Ltd.
as 12-20-2024 4:00pm EST
Stocks
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
| Founded: | 2006 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 45.5M | IPO Year: | N/A |
| Target Price: | $2.70 | AVG Volume (30 days): | 646.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.48 - $1.57 | Next Earning Date: | 11-26-2024 |
| Revenue: | $3,671,000 | Revenue Growth: | 26.02% |
| Revenue Growth (this year): | 18.61% | Revenue Growth (next year): | 54.91% |
Latest IceCure Medical Ltd. News
ICCM Breaking Stock News: Dive into ICCM Ticker-Specific Updates for Smart Investing
PR Newswire
6 days ago
Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting
PR Newswire
17 days ago
IceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results
Simply Wall St.
25 days ago
IceCure Medical Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Zacks
a month ago
IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates
PR Newswire
a month ago
IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation
PR Newswire
a month ago
IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office
PR Newswire
a month ago
IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024
PR Newswire
a month ago
IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health
Compare ICCM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ICCM IceCure Medical Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.